Cabotegravir long-acting (CAB-LA) is a game-changing medicine in preventing HIV and is the most effective form of pre-exposure prophylaxis (PrEP) currently available for people at high risk of HIV.
However, today multiple barriers hinder access to CAB-LA for many people in low- and middle-income countries, including lack of transparency around the pricing and supply of the drug by the pharmaceutical corporation ViiV Healthcare.
MSF’s Access Campaign is working in a variety of ways, including negotiating with ViiV, to try to open up equitable access to CAB-LA that could prevent potentially millions of additional HIV cases.
In these personal testimonies from Eswatini, we hear from Tholakele Madlala and Lindokuhle Dlamini about how an injectable form of PrEP such as CAB-LA could protect them better from HIV infection. We also hear from Nqobile Mmema, a Qualitative Research Assistant with MSF in Eswatini, about the need for more choice for ways people can protect themselves from HIV infection.
